Aarti Pharmalabs has informed that Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held today Monday, May 13, 2024 has approved grant of 40,000 stock options to certain eligible employees of the Company, under the APL Performance Stock Option Plan 2023 (PSOP 2023), subject to the provisions of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, at an exercise price of Rs 5 per option. Each stock option entitles the holder to apply for 1 equity share of the Company of Face Value of Rs 5 each and one-third of the total options granted shall become eligible to vest on each anniversary of grant date for 3 years, subject to continued employment and achievement of performance conditions of Vesting. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 is attached as an 'Annexure A.'
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1845.50 |
| Dr. Reddys Lab | 1275.65 |
| Cipla | 1335.25 |
| Zydus Lifesciences | 930.20 |
| Lupin | 2257.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: